Stan Berenshteyn
Stock Analyst at Wells Fargo
(2.15)
# 2,804
Out of 4,901 analysts
60
Total ratings
51.52%
Success rate
-8.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Overweight | $285 → $300 | $279.32 | +7.40% | 6 | May 29, 2025 | |
| OMCL Omnicell | Maintains: Overweight | $35 → $37 | $27.24 | +35.83% | 16 | May 23, 2025 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $10 → $8 | $7.91 | +1.14% | 3 | May 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $8 → $7 | $4.75 | +47.37% | 8 | Apr 29, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $96.18 | +29.96% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $62.05 | -11.36% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $3.74 | +167.74% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $8.00 | +87.50% | 3 | Jan 13, 2025 |
Veeva Systems
May 29, 2025
Maintains: Overweight
Price Target: $285 → $300
Current: $279.32
Upside: +7.40%
Omnicell
May 23, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $27.24
Upside: +35.83%
Teladoc Health
May 8, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $7.91
Upside: +1.14%
GoodRx Holdings
Apr 29, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.75
Upside: +47.37%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $96.18
Upside: +29.96%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $62.05
Upside: -11.36%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $3.74
Upside: +167.74%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $8.00
Upside: +87.50%